Cargando…
Loading, please waitCargando…
Loading, please waitCondition Guide
A clear, physician-led overview of how mesenchymal stem cell (MSC) therapy is being studied as a hip-preserving adjunct for avascular necrosis (osteonecrosis) of the femoral head. What the published randomized trials and 2025 meta-analytic evidence really show in pre-collapse versus collapsed disease, when MSC therapy may be considered alongside core decompression, who is and isn't a candidate — and how our team at Regeneris Therapy in Cancún, México evaluates each case under COFEPRIS oversight.
Avascular necrosis (AVN) of the femoral head — also called osteonecrosis — is a structural hip disease whose established treatments are core decompression in pre-collapse stages and total hip arthroplasty after collapse. At Regeneris Therapy in Cancún, México, MSC and bone-marrow-derived cell therapy is offered only as an investigational, physician-supervised adjunct to core decompression in early (pre-collapse) disease — never as a replacement for surgery. The strongest randomized and meta-analytic evidence shows benefit in early-stage (ARCO I–II) hips when cells are paired with mechanical support; in stage III (post-collapse) a published double-blind RCT found no clinical benefit. Every plan starts with a free medical evaluation, after which patients receive a personalized written quote — Regeneris does not publish prices.
Clinical overview
Avascular necrosis (AVN) of the femoral head — also called osteonecrosis of the femoral head (ONFH) — is a progressive disease in which the blood supply to the rounded top of the thighbone is disrupted, causing the underlying bone to die. Without timely intervention, the dead segment loses mechanical integrity, the spherical head collapses, and secondary osteoarthritis of the hip follows. The most common causes are corticosteroid use, alcohol overuse, prior hip trauma, sickle cell disease, certain autoimmune conditions, and idiopathic cases — and the condition predominantly affects adults in their 30s–50s. The disease is staged by the international ARCO system: Stage I and II are pre-collapse, Stage III is post-collapse with a subchondral fracture line, and Stage IV is end-stage secondary arthritis. The honest clinical truth is that AVN of the femoral head is a structural orthopedic disease — its established treatments are core decompression for early-stage hips and total hip arthroplasty (hip replacement) once the head has collapsed. Regenerative therapy enters this picture only as a possible adjunct to that orthopedic care in Cancún, México — never as a substitute for surgery.
Put plainly: avascular necrosis of the femoral head is a mechanical and vascular problem of the hip that orthopedic surgery is designed to address. MSC therapy in Cancún, México is offered only as a possible biological adjunct in pre-collapse disease — and only when a Regeneris physician agrees it is appropriate after reviewing your MRI, ARCO stage, surgical plan, and risk-factor profile.
What the research shows
The honest summary is: investigational, with a real but stage-dependent signal. Long-term randomized trials and 2025 meta-analytic data show benefit when bone-marrow-derived cells are combined with core decompression in early (pre-collapse) ARCO I–II disease. The same body of evidence shows no clinical benefit when the same approach is applied to ARCO III (post-collapse) hips, where total hip arthroplasty becomes the orthopedic treatment of choice. None of these studies justify marketing stem cells as a cure for AVN; they justify continued cautious investigation as a hip-preserving adjunct in carefully selected early-stage patients. The notes below summarize five representative peer-reviewed sources we discuss with patients during evaluation in Cancún, México.
The field's own founder reframed these cells as "medicinal signaling cells," arguing that their benefit comes chiefly from secreted, paracrine factors rather than from engraftment and tissue replacement. This mechanistic framing is the basis of any rational adjunct use in a necrotic bone environment — modulating inflammation and supporting the local repair environment, not single-handedly re-growing the dead segment of bone.
A prospective, double-blinded, randomized controlled study followed patients with avascular necrosis of the femoral head for 10 years comparing core decompression alone with core decompression combined with autologous bone marrow buffy coat grafting. The combined group showed a significantly longer mean survival of the native hip (102.3 months versus 78.1 months, P = 0.029), supporting a durable hip-preserving signal for cell-based adjuncts in pre-collapse disease — while the authors continue to frame the approach as one option within an orthopedic plan.
A randomized, controlled, double-blind trial in patients with ARCO stage III (post-collapse) osteonecrosis compared core decompression plus saline with core decompression plus autologous bone marrow concentrate, with 24 months of follow-up. The cell-treated group did not show a benefit on pain (VAS), WOMAC, radiologic progression, or rate of conversion to total hip replacement. The takeaway patients deserve to hear: in collapsed hips, a cell injection does not change the orthopedic trajectory, and total hip arthroplasty becomes the appropriate treatment.
A Phase I/II prospective, open-label clinical trial gave eight patients with early-stage femoral head osteonecrosis autologous bone-marrow-derived MSCs combined with core decompression, with extended follow-up to eight years. The intervention was reported as feasible and safe, with clinical improvement at twelve months; over the long arc of follow-up about half of patients eventually progressed to total hip replacement at a median of 576 days. The study is a useful real-world picture: safety profile favorable, signal of early benefit, and an honest reminder that AVN is a progressive disease and not every hip is saved.
A 2025 PLOS ONE systematic review, meta-analysis, and meta-regression aggregated ten randomized controlled trials (593 patients, 779 hips) of bone-marrow-derived stem cell therapy for avascular necrosis of the hip. Across the pooled data, cell therapy significantly reduced the risk of femoral head collapse and conversion to total hip arthroplasty and improved functional outcomes — most clearly when combined with mechanical support such as core decompression and when applied in early disease stages. The authors conclude that stem cell therapy alone, without mechanical adjuncts, did not yield comparable benefit — which is the conservative, accurate frame we use with patients in Cancún, México.
Reading the evidence together: cell-based adjuncts for AVN of the femoral head are investigational, generally well tolerated under qualified supervision, and show a stage-dependent signal — meaningful when paired with core decompression in pre-collapse ARCO I–II disease, and absent in stage III post-collapse hips. That is exactly what we tell patients in Cancún, México before they decide.
Patient selection
Candidate selection is a medical decision and depends on ARCO stage, MRI findings, risk factors, comorbidities, and goals. The lists below are a general orientation, not a self-screening tool. They reflect how our physicians in Cancún, México think about adjunct MSC therapy in the AVN-of-the-femoral-head setting.
There is no "yes for everyone" answer. The point of the free medical evaluation in Cancún, México is to honestly tell you whether MSC therapy is worth considering as a hip-preserving adjunct in your specific case — and to say no when it is not.
Regulatory framework
Regeneris Therapy is a COFEPRIS-regulated regenerative medicine clinic in Cancún, Quintana Roo, México. COFEPRIS — Comisión Federal para la Protección contra Riesgos Sanitarios — is Mexico's federal health authority (equivalent in role to the U.S. FDA). Our operating authorizations and supervised physician model are the foundation of every protocol we offer, including any MSC therapy considered as part of an AVN-of-the-femoral-head plan.
Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México. Our cell-source chain (Wharton's-jelly umbilical-cord MSCs, bone marrow, or adipose, depending on the protocol) is expanded in sterile, certified laboratory conditions before clinical use.
Every evaluation, infusion, and follow-up in Cancún, México is supervised by a licensed Mexican physician — including coordination with your treating orthopedic surgeon when appropriate. MSC therapy for AVN is never sold as an off-the-shelf product.
Our clinic is located at Av. Tulúm SM 11 MZ 1 Lote 1 Local 207, San Francisco, 77504 Cancún, Quintana Roo, México. International patients regularly fly into Cancún International Airport (CUN), and we coordinate scheduling around imaging, orthopedic timelines, and travel logistics.
The Regeneris approach
Our pathway for any AVN-of-the-femoral-head inquiry in Cancún, México is the same: a free, physician-led medical evaluation comes first, then — if and only if a Regeneris physician determines MSC therapy could appropriately complement an orthopedic hip-preserving plan — a personalized written quote is issued for your records. Regeneris does not publish prices online for any regenerative protocol.
Send us your recent MRI of the affected hip, your orthopedic surgeon's notes (if any), and your medical history including risk factors (steroid use, alcohol use, sickle cell, autoimmune disease, prior trauma). One of our physicians reviews everything personally — never a chatbot, never a sales team.
We tell you whether MSC therapy as a hip-preserving adjunct is a reasonable consideration in your specific case based on ARCO stage, MRI findings, and goals — and we tell you when it is not. If the answer is "total hip arthroplasty," we say so.
When MSC therapy is appropriate, we coordinate timing with your orthopedic surgeon — most published protocols pair cells with core decompression in pre-collapse disease. The role of the adjunct is to support, not interrupt, the established hip-preserving plan.
After the evaluation, you receive a written quote that reflects your individualized plan: which cell source, how many applications, follow-up cadence, and travel logistics for Cancún, México. Regeneris does not publish or quote standardized prices online.
This is deliberately a slower path than a typical retail medical website. AVN of the femoral head is a progressive structural disease; honest patient selection by ARCO stage and honest expectations protect outcomes more than any single injection ever could.
Honest expectations
Setting expectations is part of the medicine. Below is what the current evidence does and does not support for MSC therapy in the avascular-necrosis-of-the-femoral-head setting. Anyone — clinic or website — promising you guaranteed regeneration of a collapsed femoral head, reversal of advanced AVN "on the cells alone," or a single-shot non-surgical cure is overstating the evidence.
If a clinic tells you something stronger than this, ask to see the specific peer-reviewed source — and ask whether the trial was in pre-collapse or collapsed hips. That is exactly the conversation we expect to have with you in Cancún, México.
FAQ
The questions patients ask most about MSC therapy for avascular necrosis of the femoral head in Cancún, México.
No, not based on the published evidence. Avascular necrosis (AVN) of the femoral head is a structural and vascular disease that, in pre-collapse stages (ARCO I–II), is treated by core decompression — a hip-preserving orthopedic surgery — and in post-collapse stages (ARCO III–IV) by total hip arthroplasty. At Regeneris Therapy in Cancún, México, MSC and bone-marrow-derived cell therapy is only considered as an investigational, physician-supervised adjunct to core decompression in early-stage disease — not as a stand-alone, non-surgical cure. Any clinic promising you a non-surgical reversal of AVN of the femoral head is overstating what randomized trials and 2025 meta-analytic data actually show.
The most informative evidence comes from a 10-year prospective, double-blinded, randomized controlled trial (Li M et al., Stem Cell Res Ther 2020) in which patients with avascular necrosis of the femoral head treated by core decompression plus autologous bone marrow buffy coat grafting kept their native hips significantly longer than those treated by core decompression alone (mean survival 102.3 vs 78.1 months). A 2025 PLOS ONE systematic review and meta-analysis of ten RCTs (Novriansyah R et al., 2025) confirmed that bone marrow stem cell therapy significantly reduced femoral head collapse and conversion to total hip arthroplasty, particularly when combined with mechanical support and applied in early disease stages. We discuss these papers honestly during the medical evaluation in Cancún, México.
Yes — it is the single most important factor in patient selection. In pre-collapse ARCO Stage I or II disease, the evidence supports MSC and bone-marrow-derived cell therapy as a hip-preserving adjunct to core decompression. In Stage III post-collapse disease, a published double-blind randomized controlled trial (Hauzeur JP et al., Int Orthop 2018) found no benefit of autologous bone marrow concentrate on pain, function, radiologic progression, or conversion to hip replacement at 24 months. Once the femoral head has collapsed, the evidence-based treatment is total hip arthroplasty, not a cell injection. Our physicians in Cancún, México read your MRI and stage before any conversation about regenerative therapy.
In most published protocols, cells (autologous bone-marrow-derived MSCs, bone marrow concentrate, or allogeneic Wharton's-jelly umbilical-cord MSCs depending on the plan) are delivered around or into the necrotic segment at the time of core decompression by an orthopedic surgeon — the cell adjunct does not replace the decompression, it is timed with it. Some protocols also use intravenous or intraarticular routes for systemic anti-inflammatory support, but the strongest pre-collapse evidence pairs cells with core decompression. At Regeneris in Cancún, México this is always coordinated with your orthopedic team; we do not perform core decompression itself.
In published Phase I/II and randomized trials of MSC and bone-marrow-derived adjuncts for AVN of the femoral head, the approach has generally been reported as safe and feasible under qualified supervision, with adverse-event rates comparable to control surgery alone. As a general rule, elective MSC therapy is deferred in active or recently treated malignancy, uncontrolled immunosuppression, active uncontrolled infection, and pregnancy or breastfeeding. Disclose every medication, supplement, and diagnosis at evaluation so our physicians in Cancún, México can screen you correctly and coordinate with your orthopedic surgeon and the specialist managing your underlying disease (e.g., rheumatologist for steroid-related AVN) when relevant.
Because Regeneris Therapy operates as a COFEPRIS-regulated regenerative medicine clinic in Cancún, México — federally authorized, physician-led, and using cells expanded in certified laboratory conditions — under a regulatory framework that allows transparent access to MSC-based protocols that remain investigational in many jurisdictions. Cancún is internationally accessible via Cancún International Airport (CUN), and many of our patients combine evaluation, supervised infusion or adjunct delivery, and structured follow-up around a defined visit. Our role for AVN-of-the-femoral-head patients is to coordinate carefully with their orthopedic surgeon at home — never to compete with that care.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
Continue exploring
The full pillar on mesenchymal stem cell therapy at Regeneris in Cancún, México: cell sources, mechanism, protocols, and how to start.
ContinueHow regenerative medicine is regulated and supervised in México, and what to ask any clinic before you commit.
ContinueTravel logistics, evaluation pathway, and what to expect when coming from the U.S. or Canada for regenerative care in Cancún, México.
ContinueA 2026 comparison of regulation, available cell types, and cross-border logistics for regenerative care.
ContinueRequest a free medical evaluation with our physician team. Send imaging, orthopedic notes, and your goals.
ContinueThis page is informational and does not constitute medical advice. Avascular necrosis (osteonecrosis) of the femoral head is a structural hip disease that should be evaluated and treated by a licensed orthopedic surgeon; standard care involves hip MRI for diagnosis and staging, core decompression in pre-collapse disease, and total hip arthroplasty in post-collapse disease. Mesenchymal stem cell (MSC) and bone-marrow-derived cell therapy described on this page is investigational for AVN contexts and is offered only as a possible adjunct to standard orthopedic care after a physician evaluation. Outcomes vary by patient, ARCO stage, surgical plan, and protocol, and no individual outcome is guaranteed. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your recent hip MRI, your orthopedic surgeon's notes, and your risk-factor history. One of our physicians in Cancún, México will read your imaging, identify your ARCO stage, and tell you honestly whether MSC therapy could play a hip-preserving role for you — with a personalized written quote only after a free medical evaluation.